Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The development of anti-obesity drugs has not been straightforward. With very few drugs on the market, and bad publicity related to adverse events, obesity remains a major challenge for the pharmaceutical industry. In light of past experience with endocannabinoid-system antagonists, such as rimonabant, the authors of this Perspectives article propose that a major paradigm shift in clinical practice might be necessary to justify the use of pharmacotherapy for obesity.
Knowledge of the epidemiology, natural history, diagnosis, treatment, and rates of recurrence of nonfunctioning pituitary adenomas has greatly improved over the past few years. Wass and Karavitaki now highlight some of these advances and speculate on future avenues of research. In addition, they describe their own experience in the clinical management of patients with nonfunctioning pituitary adenomas.
